文献速递浆细胞疾病

Sost基因敲除或药理学抑制硬骨素可预防多发性骨髓瘤骨病而不影响肿瘤生长

Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.
PubMed 文献 · Leukemia · 2017-05-22

多发性骨髓瘤(MM)导致溶骨性骨病变。本研究表明,在免疫缺陷小鼠早期MM模型中敲除Sost基因可预防MM诱导的骨病;在免疫健全的已建立MM小鼠中给予抗硬骨素抗体(Scl-Ab)可增加骨量并减少骨质溶解。Sost/Scl抑制增加成骨细胞数量、刺激新骨形成并减少破骨细胞数量,且不影响体内肿瘤生长或体外抗骨髓瘤药物疗效。

要点

  • 敲除Sost基因可预防早期MM小鼠模型中的MM诱导骨病。
  • 抗硬骨素抗体增加已建立MM小鼠的骨量并减少骨质溶解。
  • Sost/Scl抑制不影响体内肿瘤生长或体外抗骨髓瘤药物疗效。

核心结论

  • 骨细胞是MM对骨骼产生有害影响的主要贡献者,骨细胞来源的Scl是治疗已建立MM诱导骨病的有前景靶点。
  • Scl不干扰MM化疗疗效,提示抗骨髓瘤药物与Scl-Ab联合治疗应能有效控制MM生长和骨病。

研究设计与样本

  • 研究采用免疫缺陷小鼠早期MM模型和免疫健全小鼠已建立MM模型,进行Sost基因敲除和抗Scl抗体(Scl-Ab)干预。

主要发现

  • 在免疫缺陷小鼠早期MM模型中,Sost基因敲除预防了MM诱导的骨病。
  • 在免疫健全的已建立MM小鼠中,给予Scl-Ab增加了骨量并减少了骨质溶解。
  • Sost/Scl抑制增加了MM定植骨中的成骨细胞数量,刺激了新骨形成,并减少了破骨细胞数量。
  • Sost/Scl抑制在体内不影响肿瘤生长,在体外不影响抗骨髓瘤药物疗效。

临床怎么用

  • 作者认为,Scl是治疗已建立MM诱导骨病的有前景靶点。
  • 作者建议,抗骨髓瘤药物与Scl-Ab联合治疗应能有效控制MM生长和骨病,为有效控制活动性MM患者的MM和骨病提供新途径。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) causes lytic bone lesions due to increased bone resorption and concomitant marked suppression of bone formation. Sclerostin (Scl), an osteocyte-derived inhibitor of Wnt/β-catenin signaling, is elevated in MM patient sera and increased in osteocytes in MM-bearing mice. We show here that genetic deletion of Sost, the gene encoding Scl, prevented MM-induced bone disease in an immune-deficient mouse model of early MM, and that administration of anti-Scl antibody (Scl-Ab) increased bone mass and decreases osteolysis in immune-competent mice with established MM. Sost/Scl inhibition increased osteoblast numbers, stimulated new bone formation and decreased osteoclast number in MM-colonized bone. Further, Sost/Scl inhibition did not affect tumor growth in vivo or anti-myeloma drug efficacy in vitro. These results identify the osteocyte as a major contributor to the deleterious effects of MM in bone and osteocyte-derived Scl as a promising target for the treatment of established MM-induced bone disease. Further, Scl did not interfere with efficacy of chemotherapy for MM, suggesting that combined treatment with anti-myeloma drugs and Scl-Ab should effectively control MM growth and bone disease, providing new avenues to effectively control MM and bone disease in patients with active MM.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Delgado-Calle J, Anderson J, Cregor MD, et al. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia. 2017. PMID: 28529307. doi:10.1038/leu.2017.152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。